CMG Pharmaceutical Co., Ltd. launches generic anticoagulant Edoxin tablets

[Financial News] CMG Pharmaceutical Co., Ltd. is entering the oral anticoagulant market. It will launch a generic product as the original drug’s patent expires and expand its cardiovascular medicine portfolio.
On the 11th, CMG Pharmaceutical Co., Ltd. announced that it had launched Edoxin tablets, an oral anticoagulant (ingredient: edoxaban; photo). Edoxin is a first generic introduced to coincide with the expiration of the compound patent for Lixiana tablets, marketed by Daiichi Sankyo Korea. It uses the same salt and formulation as the original drug, and the company confirmed its equivalence through its own bioequivalence study.
Edoxaban selectively inhibits blood coagulation factor Xa. It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, or to treat deep vein thrombosis and pulmonary embolism and prevent their recurrence.
The market is substantial. According to pharmaceutical market research firm UBIST, domestic outpatient prescription sales of Lixiana tablets totaled approximately 121.8 billion won in 2025.
The reimbursement price for Edoxin is 914 won per tablet for both the 30 mg and 60 mg strengths. This is about 36% below the original drug’s price of 1,422 won, which was lowered when the generic was launched. The company expects the product to ease the medication costs of patients requiring long-term anticoagulant treatment and expand their prescription options through generics.
CMG Pharmaceutical Co., Ltd. plans to use active pharmaceutical ingredients registered under the Drug Master File (DMF) system and directly oversee manufacturing and quality control at its own production facilities. It also plans to step up sales and marketing, focusing on general hospitals and clinics, while adjusting production and supply volumes to meet market demand.
Lee Ju-hyeong, CEO of CMG Pharmaceutical Co., Ltd., said, “Edoxin tablets are a product we launched by leveraging open innovation and our in-house production capabilities.” He added, “We will continue to bring medicines to market that meet market demand.”

[email protected] Jung Sang-hee Reporter